Brokerages Set Revvity Inc. (NYSE:RVTY) PT at $114.77

Shares of Revvity Inc. (NYSE:RVTY) have received a consensus rating of “Hold” from the eighteen ratings firms that are covering the stock, Marketbeat reports. Fourteen equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $116.5714.

Several equities analysts have recently weighed in on the company. Evercore reiterated an “outperform” rating on shares of Revvity in a research report on Wednesday, August 5th. Wolfe Research initiated coverage on Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Sanford C. Bernstein assumed coverage on Revvity in a report on Friday, June 26th. They set a “market perform” rating and a $115.00 target price for the company. KeyCorp upped their price target on Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Finally, Weiss Ratings raised shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 30th.

Revvity Price Performance

RVTY opened at $124.06 on Monday. The company has a market capitalization of $13.84 billion, a price-to-earnings ratio of 59.07, a PEG ratio of 2.31 and a beta of 1.09. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The firm has a 50-day moving average price of $117.35 and a 200-day moving average price of $102.92. Revvity has a twelve month low of $81.22 and a twelve month high of $133.00.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company had revenue of $729.69 million for the quarter, compared to analysts’ expectations of $702.96 million. During the same period in the prior year, the company posted $1.18 EPS. Revvity’s revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts expect that Revvity will post 5.36 EPS for the current year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a $0.07 dividend. The ex-dividend date is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio is currently 13.33%.

Revvity News Summary

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity agreed to acquire France-based Human Cell Design, adding human pancreatic beta-cell models for diabetes, obesity and other metabolic-disease drug discovery. The deal could strengthen Revvity’s Life Sciences portfolio and expand its preclinical research capabilities. Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
• Positive Sentiment: Zacks Research slightly raised its Revvity EPS estimates for multiple periods, including Q3 2026 to $1.28 from $1.27, Q4 2026 to $1.65 from $1.64, Q3 2027 to $1.45 from $1.42 and Q2 2028 to $1.66 from $1.62. The revisions indicate incremental confidence in earnings, although Zacks retains a “Hold” rating.
• Neutral Sentiment: Revvity presented at the Wells Fargo 21st Annual Healthcare Conference. The prepared remarks provide investors with management commentary, but the supplied report does not identify a material new forecast, transaction, or change to guidance. Revvity Wells Fargo Healthcare Conference Prepared Remarks
• Negative Sentiment: UBS initiated coverage with a “Neutral” rating, downgrading Revvity from “Buy,” even while increasing its price target to $140 from $120. The higher target suggests potential upside, but the downgrade signals that UBS sees the shares’ risk-reward balance as less compelling after the recent advance. UBS Downgrades Revvity to Neutral

Institutional Trading of Revvity

A number of large investors have recently modified their holdings of the business. New Mexico Educational Retirement Board increased its holdings in shares of Revvity by 1.9% in the 4th quarter. New Mexico Educational Retirement Board now owns 5,416 shares of the company’s stock worth $524,000 after buying an additional 100 shares during the last quarter. Allworth Financial LP lifted its stake in Revvity by 8.9% during the fourth quarter. Allworth Financial LP now owns 1,275 shares of the company’s stock worth $123,000 after purchasing an additional 104 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Revvity by 5.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,074 shares of the company’s stock worth $231,000 after purchasing an additional 106 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Revvity by 17.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company’s stock valued at $66,000 after purchasing an additional 109 shares during the last quarter. Finally, Angeles Wealth Management LLC raised its holdings in shares of Revvity by 2.0% during the 2nd quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company’s stock valued at $646,000 after buying an additional 112 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.